Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Non-Saponin Red Ginseng Components on Multi-drug Resistance

  • Published : 2007.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Multi-drug resistance (MDR) is a major problem in cancer chemotherapy and has often ended up with termination of the therapy. The aim of this study was to identify any fractions of Korean red ginseng that would be effective in modulating for MDR. Although ginsenosides have been reviewed as possible MDR modulators, the MDR modulation activity of the other component is unknown. Therefore, a red ginseng was extracted with methanol, ether, ethylacetate, and n-butanol, followed by several fractionations by silica gel chromatography. And the activity of MDR modulating for these fractions was examined via sulforrhodamine B assay. We have found that several ether fractions, as nonsaponin components are effective on MDR modulation. We have expect that these results helpful to improvement of cancer chemotherapy.

Keywords

References

  1. de Vries, E. G. E. and Pinedo, H. M.: Clinical implications of multidrug resistance to chemotherapy. p171-181. In: Ozols R. F. (ed), Molecular and Clinical Advances in Anticancer Drug Resistance. Kluwer Academic Publishers, Boston (1991)
  2. Endicott, J. A. and Ling, V.: The biochemistry of p-glycoprotein-mediated multidrug Resistance. Annu. Rev. Biochem. 58, 137-171 (1989) https://doi.org/10.1146/annurev.bi.58.070189.001033
  3. Ford, J. M. and Hait, W. N.: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199 (1990)
  4. Gottesman, M. M. and Pastan, I.: Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann. Rev. Biochem. 62, 385-427 (1993) https://doi.org/10.1146/annurev.bi.62.070193.002125
  5. Gottesman, M. M. and Pastan, I.: The multidrug transporter, a double-edged sword. J. Biol. Chem. 263, 12163-12166 (1988)
  6. Gros, P., Ben Neriah, Y., Croop, J. M. and Housman, D. E.: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature. 323, 728-731 (1986) https://doi.org/10.1038/323728a0
  7. Young, R. C.: Drug resistance: The clinical problem. p. 1-11. In: Drug resistance in cancer chemotherapy. Kluwer Academic Publishers, Boston (1989)
  8. Ozols, R. F.: Molecular and clinical advances in anticancer drug resistance, Kluwer Academic Publisher, Boston (1991)
  9. Leyland-Jones, B., Dalton, W., Fisher G. A. and Sikik, B. I.: Reversal of multidrug resistance to cancer chemotherapy. Cancer 72 (11 Suppl), 3484-3488 (1993) https://doi.org/10.1002/1097-0142(19931201)72:11+<3484::AID-CNCR2820721615>3.0.CO;2-L
  10. Robert, J.: Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur. J. Clin. Invest. 29, 536-545 (1999) https://doi.org/10.1046/j.1365-2362.1999.00495.x
  11. Cole, S. P. and Deelay, R. G.: Multidrug resistance-associated protein: sequence correction. Science 260, 879 (1993)
  12. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V. and Deeley, R. G.: Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258, 1650-1654 (1992) https://doi.org/10.1126/science.1360704
  13. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 54(2), 357-361 (1994)
  14. Bissett, D., Kerr, D. J., Cassidy, J., Meredith, P., Traugott, U. and Kaye, S. B.: Phase I and pharmacokinetic study of Dverapamil and doxorubicin. Br. J. Cancer 64(6), 1168-1171 (1991) https://doi.org/10.1038/bjc.1991.484
  15. Hyafil, F., Vergely, C., Du Vignaud, P. and Grand-Perret, T.: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53, 4595-4602 (1993)
  16. McDevitt, C. A. and Callaghan, R.: How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol. Ther. 113(2), 429-441 (2007) https://doi.org/10.1016/j.pharmthera.2006.10.003
  17. Choi, S. U., Jung, N. P. and Kim, S. C.: Effect of ginseng saponin fractions and lipopolysaccharide on the tumoricidal activity of mouse macrophages. Korean J. Ginseng Sci. 14, 364-372 (1990)
  18. Hwang, W. I., Son, H. S., Ji, R. H. and Baik, N. G.: Effects of Panax ginseng and sodium ascorbate (vitamin C) treatment on cancer cell growth. I. Synergism of combined Panax ginseng and vitamin C action in vitro. Korean J. Ginseng Sci. 13: 242-247 (1989)
  19. Kikuchi, Y., Sasa, H., Kita, T., Hirata, J., Tode, T. and Nagata, I.: Inhibition of human ovarian cancer proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anti-Cancer Drugs, 2, 63-67 (1991) https://doi.org/10.1097/00001813-199102000-00009
  20. Kim, W. and Jung, N. P.: Effects of a ginseng saponin fraction on the tumoricidal activity of murine macrophage against K562 cells. Korean J. Ginseng Sci. 13, 24-29. (1989)
  21. Yun, Y. S., Moon, H. S., Oh, Y. R., Jo, S. K., Kim, Y. J. and Yun, T. K.: Effect of red ginseng on natural killer cell activity in mice with lung adenoma induced by urethane and benzo-(a) pyrene. Cancer Detect. Prev., Suppl. 1, 301-309 (1987)
  22. Park, J. D., Kim, D. S., Kwon, H. Y., Son, S. K., Lee, Y. H., Baek, N. I., Kim, S. I., and Rhee, D. K.: Effects of ginseng saponin on modulation of multidrug resistance. Arch. Pharm. Res. 19(3), 213-218 (1996) https://doi.org/10.1007/BF02976892
  23. Kim, S. W., Kwon, H. Y., Chi, D. W., Shim, J. H., Park, J. D., Lee, Y. H., Pyo, S. and Rhee, D. K.: Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3). Biochem Pharmacol. 65, 75-82 (2003) https://doi.org/10.1016/S0006-2952(02)01446-6
  24. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S. and Boyd, M. R.: New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112 (1990) https://doi.org/10.1093/jnci/82.13.1107

Cited by

  1. Nutrigenomic approach to tackle the unpleasant journey to Helicobacter pylori-associated gastric carcinogenesis vol.12, pp.3, 2011, https://doi.org/10.1111/j.1751-2980.2011.00492.x